Aprea Therapeutics, Inc. Post-Transaction Employment and Severance Letter to Scott Coiante
This letter agreement between Aprea Therapeutics, Inc. and Scott Coiante outlines post-merger employment terms. If Mr. Coiante’s employment is terminated by the company without cause or by him for good reason within one year of the merger agreement date, he will receive 12 months of severance and benefits continuation, as specified in his existing employment agreement. All other terms of his employment agreement remain unchanged.
Exhibit 10.18
May 16, 2022
RE: Post-Transaction Employment
Dear Scott Coiante,
As a critical team member and as an inducement for your to remain employed with Aprea Therapeutics, Inc. (the “Company”) following the consummation of the transactions pursuant to that certain Agreement and Plan of Merger, dated as of May 16, 2022, by and among the Company, ATR Merger Sub I Inc., a Delaware corporation and wholly owned Subsidiary of the Company, ATR Merger Sub II LLC, a Delaware limited liability company and wholly owned Subsidiary of the Company, and Atrin Pharmaceuticals Inc., a Delaware corporation (the “Merger Agreement”). If your employment is terminated by the Company without “cause” or by your due to “good reason” (each as defined in your Employment Agreement with the Company, dated as of September 26, 2019 (the “Employment Agreement”)) on or prior to the one-year anniversary of the date of the Merger Agreement, you will be eligible to receive severance and benefits continuation under the Employment Agreement based on 12-months of severance. Except as modified herein, your Employment Agreement remains in effect.
[Signature Page Follows.]
Sincerely,
APREA THERAPEUTICS, INC.
By: /s/ Christian S. Schade
Name: Christian S. Schade
Title: Chief Executive Officer
Accepted and Agreed to By:
/s/ Scott Coiante May 16, 2022
Scott CoianteDate
